TY  - JOUR
A1  - Grunicke, H.
A1  - Pyerin, W.
A1  - Eisenbrand, G.
A1  - Havemann, K.
A1  - Rabes, H. M.
A1  - Molling, K.
A1  - Schwab, M.
A1  - Lutz, Werner K.
A1  - Wahrendorf, J.
A1  - Schirrmacher, V.
T1  - 7th International Symposium of the Division of Experimental Cancer Research (AEK) of the German Cancer Society : [Meeting report]
N2  - No abstract available
KW  - Toxikologie
Y1  - 1994
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-60651
ER  - 
TY  - JOUR
A1  - Willms, A. G.
A1  - Schwab, R.
A1  - von Websky, M. W.
A1  - Berrevoet, F.
A1  - Tartaglia, D.
A1  - Sörelius, K.
A1  - Fortelny, R. H.
A1  - Björck, M.
A1  - Monchal, T.
A1  - Brennfleck, F.
A1  - Bulian, D.
A1  - Beltzer, C.
A1  - Germer, C. T.
A1  - Lock, J. F.
T1  - Factors influencing the fascial closure rate after open abdomen treatment: Results from the European Hernia Society (EuraHS) Registry. Surgical technique matters
JF  - Hernia
N2  - Purpose
Definitive fascial closure is an essential treatment objective after open abdomen treatment and mitigates morbidity and mortality. There is a paucity of evidence on factors that promote or prevent definitive fascial closure.

Methods
A multi-center multivariable analysis of data from the Open Abdomen Route of the European Hernia Society included all cases between 1 May 2015 and 31 December 2019. Different treatment elements, i.e. the use of a visceral protective layer, negative-pressure wound therapy and dynamic closure techniques, as well as patient characteristics were included in the multivariable analysis. The study was registered in the International Clinical Trials Registry Platform via the German Registry for Clinical Trials (DRK00021719).

Results
Data were included from 630 patients from eleven surgical departments in six European countries. Indications for OAT were peritonitis (46%), abdominal compartment syndrome (20.5%), burst abdomen (11.3%), abdominal trauma (9%), and other conditions (13.2%). The overall definitive fascial closure rate was 57.5% in the intention-to-treat analysis and 71% in the per-protocol analysis. The multivariable analysis showed a positive correlation of negative-pressure wound therapy (odds ratio: 2.496, p < 0.001) and dynamic closure techniques (odds ratio: 2.687, p < 0.001) with fascial closure and a negative correlation of intra-abdominal contamination (odds ratio: 0.630, p = 0.029) and the number of surgical procedures before OAT (odds ratio: 0.740, p = 0.005) with DFC.

Conclusion
The clinical course and prognosis of open abdomen treatment can significantly be improved by the use of treatment elements such as negative-pressure wound therapy and dynamic closure techniques, which are associated with definitive fascial closure.
KW  - open abdomen
KW  - peritonitis
KW  - fascial closure
KW  - hernia
KW  - abdominal compartment syndrome
KW  - abdominal trauma
KW  - burst abdomen
KW  - NPWT
KW  - VAC
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-234871
SN  - 1265-4906
VL  - 26
IS  - 1
ER  - 
TY  - JOUR
A1  - Seal, Rishav
A1  - Schwab, Lara S. U.
A1  - Chiarolla, Cristina M.
A1  - Hundhausen, Nadine
A1  - Klose, Georg Heinrich
A1  - Reu-Hofer, Simone
A1  - Rosenwald, Andreas
A1  - Wiest, Johannes
A1  - Berberich-Siebelt, Friederike
T1  - Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis
JF  - Frontiers in Immunology
N2  - In inflammatory bowel disease, dysregulated T cells express pro-inflammatory cytokines. Using a chronic azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis model resembling ulcerative colitis, we evaluated whether and when treatment with the Janus kinase (JAK) inhibitor tofacitinib could be curative. Comparing the treatment with two and three cycles of tofacitinib medication in drinking water – intermittently with DSS induction – revealed that two cycles were not only sufficient but also superior over the 3-x regimen. The two cycles of the 2-x protocol paralleled the second and third cycles of the longer protocol. T cells were less able to express interferon gamma (IFN-γ) and the serum levels of IFN-γ, interleukin (IL)-2, IL-6, IL-17, and tumor necrosis factor (TNF) were significantly reduced in sera, while those of IL-10 and IL-22 increased under the 2-x protocol. Likewise, the frequency and effector phenotype of regulatory T cells (Tregs) increased. This was accompanied by normal weight gain, controlled clinical scores, and restored stool consistency. The general and histologic appearance of the colons revealed healing and tissue intactness. Importantly, two phases of tofacitinib medication completely prevented AOM-incited pseudopolyps and the hyper-proliferation of epithelia, which was in contrast to the 3-x regimen. This implies that the initial IBD-induced cytokine expression is not necessarily harmful as long as inflammatory signaling can later be suppressed and that time-restricted treatment allows for anti-inflammatory and tissue-healing cytokine activities.
KW  - anti-inflammatory cytokines
KW  - AOM/DSS
KW  - pro-inflammatory cytokines
KW  - effector Treg (eTreg)
KW  - chronic IBD model
KW  - JAK inhibitor
KW  - tofacitinib
KW  - treatment regimens
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-317815
VL  - 14
ER  -